Verification evidence is still being completed.
PDF / print export
SyVento BioTech Sp. z o.o.
Skawina, Poland
- Verified lead
- Kajetan Bartosik
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- mRNA Formulation, Lipid Nanoparticle Manufacturing, and Preclinical to Clinical CDMO Services
- Review cycle
- 24 April 2026
- Full address
- ul. Za Gora 19, 32-050 Skawina, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- SyVento BioTech CEO-appointment announcement naming Kajetan Bartosik as Chief Executive Officer.
- Editorial note
- Skawina GMP-capable mRNA and LNP CDMO with named CEO, Cytiva FlexFactory platform, and documented preclinical-to-clinical service scope.
mRNA Formulation, Lipid Nanoparticle Manufacturing, and Preclinical to Clinical CDMO Services
GMP-capable mRNA facility, Cytiva FlexFactory platform, Contract Pharma facility-opening coverage
Skawina GMP-capable mRNA and LNP CDMO with named CEO, Cytiva FlexFactory platform, and documented preclinical-to-clinical service scope.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Skawina GMP-capable mRNA and LNP CDMO with named CEO, Cytiva FlexFactory platform, and documented preclinical-to-clinical service scope.
Contact & location
- Website
- syvento.com
- Lead
- Kajetan Bartosik (verified ↗)
- Compliance
- GMP-capable mRNA facility
- Last reviewed
- 24 Apr 2026 (2mo ago)
- Scale
- GMP-capable mRNA and LNP manufacturing
- Capabilities
- LNP Formulation · mRNA Drug Substance and Drug Product · Preclinical to Clinical CDMO Delivery
- Founded
- 2014
- Headcount
- 1-10
mRNA Formulation, Lipid Nanoparticle Manufacturing, and Preclinical to Clinical CDMO Services
Skawina GMP-capable mRNA and LNP CDMO with named CEO, Cytiva FlexFactory platform, and documented preclinical-to-clinical service scope.
Editorial note
SyVento BioTech anchors Polish mRNA and LNP CDMO capacity with a named CEO, a Cytiva FlexFactory platform, and documented facility opening coverage in Contract Pharma.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Verification details
Clinical profileSTATUS: VERIFIED APRIL 2026
Kajetan Bartosik
Chief Executive Officer
Full addressul. Za Gora 19, 32-050 Skawina, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
SyVento registered-office change notice listing Za Gora 19 in Skawina.
Open sourceGMP-capable mRNA and LNP manufacturing
Skawina, Poland. mRNA Formulation, Lipid Nanoparticle Manufacturing, and Preclinical to Clinical CDMO Services. Review completed on 24 Apr 2026.
Polish Office for Registration of Medicinal Products and EMA for GMP oversight
GMP-capable mRNA facility, Cytiva FlexFactory platform, Contract Pharma facility-opening coverage
Capabilities
LNP Formulation
mRNA Drug Substance and Drug Product
Preclinical to Clinical CDMO Delivery
Sources
The official sources used to verify this profile.
Infrastructure
Cytiva FlexFactory platform
LNP formulation workflow
mRNA drug substance and drug product
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
Frequently asked questions
- Where is SyVento BioTech Sp. z o.o. located?
- SyVento BioTech Sp. z o.o. operates from ul. Za Gora 19, 32-050 Skawina, Poland, Skawina, Poland.
- Who runs SyVento BioTech Sp. z o.o.?
- SyVento BioTech Sp. z o.o. is led by Kajetan Bartosik, Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does SyVento BioTech Sp. z o.o. hold?
- SyVento BioTech Sp. z o.o. is documented under GMP-capable mRNA facility.
- What does SyVento BioTech Sp. z o.o. do?
- Skawina GMP-capable mRNA and LNP CDMO with named CEO, Cytiva FlexFactory platform, and documented preclinical-to-clinical service scope. Core capabilities: LNP Formulation, mRNA Drug Substance and Drug Product, Preclinical to Clinical CDMO Delivery.
Editorial context
Related technical briefs
Briefs that name Skawina as a covered market or city.